Literature DB >> 21947361

Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice.

Nan N Zhang1, Nong Y Huang, Xi K Zhou, Xiao L Luo, Chang Y Liu, Yan Zhang, Ji Qiu, Yin B Zhang, Xiu Teng, Can Luo, Xian C Chen, Bing Kan, Yong Q Mao, Ai P Tong, Yu Q Wei, Jiong Li.   

Abstract

OBJECTIVE: Mice injected with Bacillus Calmette-Guérin (BCG) were challenged with lipopolysaccharide (LPS) to induce inflammatory liver injury. This study was performed to explore the protective effects of interleukin (IL)-4 against liver injury induced by BCG and LPS in mice.
MATERIALS AND METHODS: Mice injected with BCG (125 mg/kg) were challenged with LPS (10 μg/kg) to induce the model of inflammatory liver injury. Half an hour after injection of LPS, mice were subcutaneously administered rmIL-4 at 5 and 0.5 μg/kg, respectively. Liver injury was evaluated by serum transaminase assay and H & E staining. Liver cytokine concentrations were determined by enzyme-linked immunosorbent assay, and intrahepatic cytokine and iNOS mRNA levels by reverse transcriptase polymerase chain reaction. Intrahepatic apoptosis was evaluated by terminal deoxynucleotidyl transferase mediated nick end labeling. NF-κB p65 and ERK signal pathway was detected by Western-blotting. NF-κB signal pathway was also detected by electrophoretic mobility shift assay.
RESULTS: IL-4 reduced the serum ALT, AST and LDH, alleviated the inflammatory cells infiltration, down regulated the expression of TNF-α, IL-1β, IFN-γ, IL-6 and iNOS mRNA in liver, and alleviated hepatic glutathione depletion (GSH). In addition, IL-4 displayed inhibition of extracellular signal-regulated kinase phosphorylation and NF-κB activation.
CONCLUSION: IL-4 may protect mice against BCG/LPS-induced immune liver injury, besides ERK and NF-κB signal pathways were involved in the effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947361     DOI: 10.1007/s00011-011-0383-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  48 in total

Review 1.  Anti-inflammatory cytokines.

Authors:  S M Opal; V A DePalo
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

Review 2.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Effect and mechanisms of FR167653, a dual inhibitor of TNF-alpha and IL-1, on BCG plus LPS induced-liver injury.

Authors:  H W Yao; L Yue
Journal:  Inflamm Res       Date:  2005-11       Impact factor: 4.575

4.  Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis.

Authors:  Maria L Olleros; Dominique Vesin; Agathe L Fotio; Marie-Laure Santiago-Raber; Sébastien Tauzin; David E Szymkowski; Irene Garcia
Journal:  J Hepatol       Date:  2010-08-04       Impact factor: 25.083

5.  Prevention of hepatic injury by a traditional Chinese formulation, BJ-JN, in mice treated with Bacille-Calmette-Guérin and lipopolysaccharide.

Authors:  Yuhong Zou; Yan Yang; Jun Li; Weiping Li; Qiang Wu
Journal:  J Ethnopharmacol       Date:  2006-04-19       Impact factor: 4.360

6.  Short-term ethanol exposure increases the expression of Kupffer cell CD14 receptor and lipopolysaccharide binding protein in rat liver.

Authors:  T A Lukkari; H A Järveläinen; T Oinonen; E Kettunen; K O Lindros
Journal:  Alcohol Alcohol       Date:  1999 May-Jun       Impact factor: 2.826

7.  Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist.

Authors:  E Vannier; L C Miller; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

8.  Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver.

Authors:  De-Xiang Xu; Wei Wei; Mei-Fang Sun; Cheng-Yi Wu; Jian-Ping Wang; Ling-Zhen Wei; Cheng-Fan Zhou
Journal:  Free Radic Biol Med       Date:  2004-07-01       Impact factor: 7.376

9.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Authors:  Dawn E Post; Eric M Sandberg; Michele M Kyle; Narra Sarojini Devi; Daniel J Brat; Zhiheng Xu; Mourad Tighiouart; Erwin G Van Meir
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-gamma-deficient mice by a concomitant reduction of TNF-alpha, IL-12, and IL-18 production.

Authors:  H Tsuji; N Mukaida; A Harada; S Kaneko; E Matsushita; Y Nakanuma; H Tsutsui; H Okamura; K Nakanishi; Y Tagawa; Y Iwakura; K Kobayashi; K Matsushima
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  3 in total

1.  Activation of natural killer T cells contributes to triptolide-induced liver injury in mice.

Authors:  Xin-Zhi Wang; Ru-Feng Xue; Shen-Ye Zhang; Ya-Ting Zheng; Lu-Yong Zhang; Zhen-Zhou Jiang
Journal:  Acta Pharmacol Sin       Date:  2018-07-16       Impact factor: 6.150

2.  Interleukin-35 Attenuates D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing Interleukin-10 Production in Kupffer Cells.

Authors:  Xing-Feng Zheng; Xiao-Yan Hu; Bing Ma; He Fang; Fang Zhang; Yan-Fei Mao; Feng-Yong Yang; Shi-Chu Xiao; Zhao-Fan Xia
Journal:  Front Pharmacol       Date:  2018-08-24       Impact factor: 5.810

3.  Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis.

Authors:  Jingjing Li; Yujing Xia; Tong Liu; Junshan Wang; Weiqi Dai; Fan Wang; Yuanyuan Zheng; Kan Chen; Sainan Li; Huerxidan Abudumijiti; Zheng Zhou; Jianrong Wang; Wenxia Lu; Rong Zhu; Jing Yang; Huawei Zhang; Qin Yin; Chengfen Wang; Yuqing Zhou; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.